戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ing conditioning regimens that are minimally myelotoxic.
2      When treated with a cell cycle-specific myelotoxic agent, the animals reconstituted with PrP-nul
3  could potentially avoid the requirement for myelotoxic agents altogether.
4  stimulation with differentiating cytokines, myelotoxic agents and inflammatory substances.
5 hich become progressively resistant to these myelotoxic and immunosuppressive agents.
6 ential role for FAK in regulating hemolytic, myelotoxic, as well as acute inflammatory stress respons
7 nd reinfusion of the modified HSCs following myelotoxic bone marrow conditioning.
8 tologic malignancy (P <.001), total previous myelotoxic chemotherapy (P <.001), T-cell dose (P =.03),
9 ading cause of morbidity and mortality after myelotoxic chemotherapy or radiation exposure.
10 e, and leucovorin (ProMACE-CytaBOM) when the myelotoxic drugs cyclophosphamide, doxorubicin, etoposid
11  both drugs failed to mitigate hydroxyurea's myelotoxic effects and caused loss of HbF induction.
12                                              Myelotoxic effects were the main adverse reactions.
13 /wk for 8 weeks to nonhuman primates was not myelotoxic, hypomethylated DNA in the gamma-globin gene
14                                              Myelotoxic injury in the bone marrow (BM) as a consequen
15  Exposing the animals to cell cycle-specific myelotoxic injury resulted in premature death due to hem
16 owed accelerated hematopoietic recovery from myelotoxic injury, and HO-1(+/-) HSCs repopulated lethal
17 al for hematopoiesis and for protection from myelotoxic injury.
18  cells have shown that 100 cGy, although not myelotoxic, is stem cell toxic, and indicate that the fi
19  allograft survival, it was not nephrotoxic, myelotoxic, or lipotoxic and did not increase CsA-induce
20 ot impact HSC function under steady-state or myelotoxic stress conditions (such as arsenic or radiati
21 ogenitor cells during steady state and after myelotoxic stress in vivo.
22 mpers the study of its pathophysiology under myelotoxic stress induced by drugs, radiation or genetic
23  who had received fewer than three cycles of myelotoxic therapy for chronic myeloid leukemia or myelo
24 neutropenia even during periods of full-dose myelotoxic therapy.
25                                              Myelotoxic treatments for oncologic diseases are often c